Case Report

Femoral metastasis of papillary carcinoma of the ovary -A rare incidental finding

Bushra Siddiqui¹, Suhailur Rahman¹, Sumbul Warsi¹, Kafil Akhtar^{1,*}

¹Dept. of Pathology, Jawaharlal Nehru Medical College, Aligarh Muslim University, Aligarh, Uttar Pradesh, India

ARTICLE INFO

Article history:

Received 15-01-2021

Accepted 11-02-2021

Available online 10-03-2021

Keywords:

Bone

Femur

Metastasis

Ovarian cancer

Immunohistochemistry

ABSTRACT

Epithelial ovarian cancer normally spreads transcoelomically via the peritoneal cavity and then, in more advanced stages, to the intra-abdominal lymph nodes and the liver and lung parenchyma. Bone metastasis is an extremely rare initial presentation in patients with primary carcinoma of the ovary and is associated with poor prognosis. Herein we report a rare case of femoral metastasis of papillary carcinoma of the ovary in a 49-year-old female, who presented to the orthopaedics clinic with complaints of pain and swelling around the left knee joint since 2 months. X ray and MRI of left leg showed a diffuse soft tissue swelling and osteolytic lesions in the lower femur around the condyles with focal cortical destruction. Fine needle aspiration biopsy of the lesion was suggestive of metastatic adenocarcinoma. Subsequent ultrasonography of the lower abdomen showed a hypoechoic shadow in the left ovary. Local surgical excision with left oophorectomy was performed. After histopathologic and immunohistochemical examination from both the sites, a final diagnosis of primary papillary adenocarcinoma of the ovary with femoral metastasis was given. She was treated with 6 cycles of adjuvant combination chemotherapy of Paclitaxel 150 mg/m² and Cisplatin 50 mg/m² and a good response was seen. This case is unique in presentation of bony femoral metastasis with silent epithelial ovarian carcinoma.

© This is an open access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>) which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

1. Introduction

Epithelial ovarian cancer generally presents with already advanced disease at the time of diagnosis and is accompanied by poor prognosis with increased mortality.¹ Ovarian cancer is responsible for almost half of deaths from cancer of the female genital tract because malignant tumours often spread outside the ovary by the time a definite diagnosis is made.²

They spread predominantly directly within the pelvis and abdomen, but lymphatic and hematogenous spread may also occur.³ The most common sites of distant metastasis are the pleura, liver, lung and lymph nodes.^{2,4} However bony metastases from ovarian cancer are rare. They tend to affect the axial skeleton and are associated with abdomino-pelvic disease.³ Median survival of patients with bony metastasis from ovarian malignancy ranges from 4 to 8 months.^{5,6}

Therefore early diagnosis and optimal management is crucial.

2. Case Report

A 49-year-old woman presented to the Orthopaedics Clinic with complaints of pain and swelling around the left knee joint since 2 months. Her appetite was decreased and she had mild abdominal pain for the same duration. There was no history of menstrual irregularities. On examination, there was absence of a left ankle jerk, with left sciatic-nerve irritation but no sensory or motor abnormalities. Her built was normal with no pallor or icterus. On abdominal examination, mild ascitis was noted with no appreciable organomegaly or lymphadenopathy.

X ray of left leg showed a diffuse soft tissue swelling around the knee joint with focal cortical destruction. MRI examination showed foci of osteolytic lesions in the lower femur around the condyles. FNAC of the lesion

* Corresponding author.

E-mail address: drkafilakhtar@gmail.com (K. Akhtar).

revealed cohesive clusters of round to oval tumor cells with hyperchromatic nucleus and scant eosinophilic cytoplasm with nuclear moulding and crowding at places. At places acini formation was also appreciated (Figure 1). A cytologic impression suggestive of malignancy favouring metastatic adenocarcinoma was given. The patient was advised further investigations and a bone biopsy was performed. Subsequent ultrasonography of the lower abdomen showed a hypoechoic shadow in the left ovary. Left oophorectomy was performed under general anesthesia.

Grossly the ovarian mass was solid to cystic, 4.3x 3.5 cm in size and well encapsulated. Microscopically tissue sections showed papillary architecture of tumor, with minimal cytologic atypia lined by stratified round to oval tumor cells with hyperchromatic nucleus and mild eosinophilic cytoplasm (Figure 2). Immunohistochemical examination revealed strong nuclear positivity of tumors cells for estrogen receptor, diffuse membranous positivity for CK 7 (Figure 3) and PAX-8 (Figure 4) and negative immunoexpression for TTF-1 (Figure 5). The bone biopsy tissue examination revealed a similar morphological appearance and immunohistochemical phenotype to the left ovarian specimen. A final diagnosis of papillary adenocarcinoma of the ovary with femoral metastasis was made. She was treated with 6 cycles of combination chemotherapy of Paclitaxel 150 mg/m² and Cisplatin 50 mg/m² and a good response was seen. Our patient is doing well after 6 months of follow up period.

Fig. 1: FNAC smears of the lesion revealed cohesive clusters of round to oval tumor cells with hyperchromatic nucleus and scant eosinophilic cytoplasm with nuclear moulding and crowding at places. At places acini formation was also appreciated. Hematoxylin and Eosin x 10X.

3. Discussion

Ovarian cancer with bone metastasis is a rare condition with a poor prognosis. Pathological diagnosis of early bony lesions is essential in a case of ovarian cancer. Also systemic and local disease should be treated with early surgical intervention or palliative therapy for better survival of the

Fig. 2: Microscopically tissue sections showed papillary architecture of tumor, with minimal cytologic atypia lined by stratified round to oval tumor cells with hyperchromatic nucleus and mild eosinophilic cytoplasm. Hematoxylin and Eosin x 10X.

Fig. 3: Immunohistochemical expression of CK 7 showed moderate membranous positivity of tumor cells. IHC CK7 x 10X.

Fig. 4: Immunohistochemical expression of PAX-8 showed strong membranous positivity of tumor cells. IHC PAX-8 x 10X.

Fig. 5: Immunohistochemistry showed negative expression of TTF-1 in tumors cells. IHC TTF-1x 10X.

patients.³

Ovarian cancer with extra-abdominal metastasis is rare and accounts about 3% of the cases.¹ Several theories have been put forward to explain the occurrence of bony metastases in ovarian cancer. These include direct invasion from underlying growth, accidental implantation of tumor cells during surgery (iatrogenic), and through the lymphatics and hematogenous route.^{4,5} Russel et al have reported four cases of bone metastasis in their study on 336 cases of epithelial ovarian cancer.³ The median time interval between diagnosis of epithelial ovarian carcinoma and presentation of bony metastases is 44 months.¹ Seidman et al have reported 0.06-0.19% incidence of bony metastasis with epithelial ovarian cancer.⁵ Barcena and Oliva have reported 7 cases of bony metastasis in 113 ovarian cancer patients.⁷ Bone metastasis was seen in high grades tumors only and the most common site observed was thoracic vertebra, followed by clavicle and axial skeleton.⁷ Cormio et al reported the incidence of distant bony metastases in stage IV ovarian cancer patients.⁸ Seidman et al had observed a greater incidence of bone metastasis in patients with positive pelvic and para aortic lymph nodes.⁵ The present case did not have any associated lymphadenopathy, but bony pain with secondaries was the first presentation.

Immunohistochemistry is essential for histologic diagnosis of suspected metastases, especially with an unknown primary.^{6,7,9} In women with a history of gynecologic tumor and papillary architecture of the metastatic foci, PAX8 is very helpful as it is specific marker for neoplasms of Müllerian duct origin.⁹ In our patient, possibility of primary thyroid cancer was excluded by negative immunoexpression of thyroglobulin, a marker highly specific of follicular thyroid neoplasms. Thus, we made a final diagnosis of metastatic papillary adenocarcinoma of the left ovary.

Effective chemotherapy for the treatment of ovarian carcinoma has prolonged patient survival.¹⁰ Besides chemotherapy, symptomatic management of extra-abdominal metastases should be considered. Surgical

excision should be considered in selected patients after evaluating the patient's general condition. Bone lesions on the extremities may be safer to remove by surgery.^{11,12}

The bony metastases tend to appear late in the course of the disease with a poor prognosis and decreased survival.^{12,13} Long-term surveillance should be continued in women with serous adenocarcinoma ovary as relapse after initial diagnosis has been reported to be as long as 28 years.¹⁴

4. Conclusions

This case highlights the importance of a thorough history, abdominal examination and investigations during orthopaedic admission so that such cases are not missed and patients mismanaged, especially as median survival is low with a rapid clinical deterioration. Pathologists and radiologists should not exclude primary ovarian carcinoma in a case of bony metastasis and long-term surveillance of women with epithelial ovarian cancer is recommended.

5. Source of Funding

No financial support was received for the work within this manuscript.

6. Conflict of Interest

The authors declare they have no conflict of interest.

References

- Hannibal CG, Vang R, Junge J, Frederiksen K, Kurman RJ, Kjaer SK. A nationwide study of ovarian serous borderline tumors in Denmark 1978–2002. Risk of recurrence, and development of ovarian serous carcinoma. *Gynecologic Oncology*. 2017;144(1):174–180. Available from: <https://dx.doi.org/10.1016/j.ygyno.2016.11.007>. doi:10.1016/j.ygyno.2016.11.007.
- Vang R, Hannibal CG, Junge J, Frederiksen K, Kjaer SK, Kurman RJ. Long-term Behavior of Serous Borderline Tumors Subdivided Into Atypical Proliferative Tumors and Noninvasive Low-grade Carcinomas. *American Journal of Surgical Pathology*. 2017;41(6):725–737. Available from: <https://dx.doi.org/10.1097/pas.0000000000000824>. doi:10.1097/pas.0000000000000824.
- Petty RD, Gilbert F, Hutcheon AW, Sarkar TK, McNally O, Parkin D. Bone metastasis from epithelial ovarian carcinoma. *The Lancet Oncology*. 2002;3(8):513–513. Available from: [https://dx.doi.org/10.1016/s1470-2045\(02\)00821-5](https://dx.doi.org/10.1016/s1470-2045(02)00821-5). doi:10.1016/s1470-2045(02)00821-5.
- Deavers MT, Gershenson DM, Tortolero-Luna G, Malpica A, Lu KH, Silva EG. Micropapillary and Cribriform Patterns in Ovarian Serous Tumors of Low Malignant Potential. *The American Journal of Surgical Pathology*. 2002;26(9):1129–1141. Available from: <https://dx.doi.org/10.1097/00000478-200209000-00003>. doi:10.1097/00000478-200209000-00003.
- Seidman JD, Bell DA, Crum CP, Gilks CB, Kurman RJ, Levine DA. Tumours of the ovary: serous tumours. *WHO classification of Tumours of female reproductive organs*. 2014;p. 15–24.
- Singer G, Stöhr R, Cope L, Dehari R, Hartmann A, Cao DF, et al. Patterns of p53 Mutations Separate Ovarian Serous Borderline Tumors and Low- and High-grade Carcinomas and Provide Support for a New Model of Ovarian Carcinogenesis. *American Journal of Surgical Pathology*. 2005;29(2):218–224.

- Available from: <https://dx.doi.org/10.1097/01.pas.0000146025.91953.8d>. doi:10.1097/01.pas.0000146025.91953.8d.
7. Bárcena C, Oliva E. WT1 Expression in the Female Genital Tract. *Advances in Anatomic Pathology*. 2011;18(6):454–465. Available from: <https://dx.doi.org/10.1097/pap.0b013e318234aaed>. doi:10.1097/pap.0b013e318234aaed.
 8. Cormio G, Rossi C, Cazzolla A. Distant metastases in ovarian carcinoma. *Int J Gynecol Cancer*. 2003;13:125–129.
 9. Ozcan A, Liles N, Coffey D, Shen SS, Truong LD. PAX2 and PAX8 Expression in Primary and Metastatic Müllerian Epithelial Tumors. *American Journal of Surgical Pathology*. 2011;35(12):1837–1847. Available from: <https://dx.doi.org/10.1097/pas.0b013e31822d787c>. doi:10.1097/pas.0b013e31822d787c.
 10. Ahn G, Folkins AK, Mckenney JK, Longacre TA. Low-grade serous carcinoma of the ovary: Clinicopathologic analysis of 52 invasive cases and identification of a possible non invasive intermediate lesion. *Am J Surg Pathol*. 2016;40:1161–1165.
 11. Xing D, Jenson EG, Zwick CA, Rodriguez FJ, Kurman RJ. Atypical Proliferative (Borderline) Serous Tumor in the Brain. *International Journal of Gynecological Pathology*. 2018;37(1):52–56. Available from: <https://dx.doi.org/10.1097/pgp.0000000000000389>. doi:10.1097/pgp.0000000000000389.
 12. Tsang YT, Deavers MT, Sun CC, Kwan SY, Kuo E, Malpica A, et al. KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma. *The Journal of Pathology*. 2013;231(4):449–456. Available from: <https://dx.doi.org/10.1002/path.4252>. doi:10.1002/path.4252.
 13. Farley J, Brady WE, Vathipadiekal V, Lankes HA, Coleman R, Morgan MA, et al. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. *The Lancet Oncology*. 2013;14(2):134–140. Available from: [https://dx.doi.org/10.1016/s1470-2045\(12\)70572-7](https://dx.doi.org/10.1016/s1470-2045(12)70572-7). doi:10.1016/s1470-2045(12)70572-7.
 14. Menczer J, Schreiber L, Peled O, Levy T. Very late recurrence (after more than 20 years) of epithelial ovarian carcinoma: case report and literature review. *Archives of Gynecology and Obstetrics*. 2015;291(6):1199–1203. Available from: <https://dx.doi.org/10.1007/s00404-014-3597-6>. doi:10.1007/s00404-014-3597-6.

Author biography

Bushra Siddiqui, Assistant Professor

Suhailur Rahman, Assistant Professor

Sumbul Warsi, Junior Resident

Kafil Akhtar, Professor

Cite this article: Siddiqui B, Rahman S, Warsi S, Akhtar K. Femoral metastasis of papillary carcinoma of the ovary -A rare incidental finding. *IP J Diagn Pathol Oncol* 2021;6(1):80-83.